Cancer Research The Future of Cancer Research: Science and Patient Impact  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 46, 2230-2235, May 1, 1986]
© 1986 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Samuels, L. L.
Right arrow Articles by Sirotnak, F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Samuels, L. L.
Right arrow Articles by Sirotnak, F. M.

Hydrolytic Cleavage of Methotrexate {gamma}-Polyglutamates by Folylpolyglutamyl Hydrolase Derived from Various Tumors and Normal Tissues of the Mouse1

L. L. Samuels, L. J. Goutas, D. G. Priest, J. R. Piper and F. M. Sirotnak2

Memorial Sloan-Kettering Cancer Center and Sloan-Kettering Division, Graduate School of Medical Sciences, New York, New York 10021 [L. L. S., L. J. G., F. M. S.]; Department of Biochemistry, Medical University of South Carolina, Charleston, South Carolina 29425 [D. G. P.]; and Organic Chemistry Research, Southern Research Institute, Birmingham, Alabama 35255 [J. R. P.]

Folylpolyglutamate hydrolase (folyl hydrolase) activity derived from murine tumors and various normal tissues was measured by means of high performance liquid chromatography using methotrexate polyglutamates as substrate. Enzyme-mediated hydrolysis was considerably greater (10–20-fold) on a specific activity basis in extracts from all normal mouse tissues (kidney > bone marrow > small intestine {cong} liver) than from tumor cells (Sarcoma 180 > Ehrlich {cong} L1210 cells). Enzyme preparations from purified absorptive and crypt cell epithelium from mouse small intestine exhibited comparable levels of specific activity and were greater than that derived from the total organ. Folyl hydrolase from mouse kidney showed mixed endo- and exopeptidase activity while that derived from all other normal tissues and tumor cells was consistent with endopeptidase activity. Levels of cell-free folyl hydrolase activity derived from tumor cells varied substantially with the phase of growth in vivo. Also, levels were appreciably lower from the same cells grown in vitro. Hydrolysis by crude or partially purified enzyme preparations from mouse small intestine or tumor cells conformed to Michaelis-Menten kinetics (single saturable component). Rates of hydrolysis and Km values were proportional to {gamma}-glutamyl chain length in the case of L1210 cell-derived enzyme but not for enzyme derived from small intestine. Km values derived for 4-amino-10-methylpteroyldiglutamate were the same [Km = 80.4 ± 9 (SE) µM] for small intestine and L1210 cells. However, with 4-amino-10-methylpteroyltetraglutamate Km values were 3-fold lower for tumor cell preparations and 8-fold lower for preparations derived from small intestine. Fourfold lower Km values for 4-amino-10-methylpteroyldiglutamate were obtained with enzyme derived from Sarcoma 180 cells as compared to the enzyme from L1210 or intestinal cells. Varying levels of folyl hydrolase activity for methotrexate polyglutamates in cell-free preparations from different tumor cells appeared to reflect differences in in situ hydrolytic activity shown for the same substrate when internalized. The relevance of these results to antifolate pharmacology and, specifically, to a role for polyglutamates of 4-aminofolate compounds in determining cytotoxicity and selective antitumor activity of these agents is discussed.

1 Supported in part by Grants CA 08748, CA 18856, CA 22764, and CA 25236 from the National Cancer Institute, USPHS, and the Elsa U. Pardee Foundation.

2 To whom requests for reprints should be addressed, at Laboratory for Molecular Therapeutics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.

Received 9/ 9/85. Revised 1/14/86. Accepted 1/20/86.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
J. C. Panetta, A. Wall, C.-H. Pui, M. V. Relling, and W. E. Evans
Methotrexate Intracellular Disposition in Acute Lymphoblastic Leukemia: A Mathematical Model of {gamma}-Glutamyl Hydrolase Activity
Clin. Cancer Res., July 1, 2002; 8(7): 2423 - 2429.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. C. Farrugia, G. W. Aherne, L. Brunton, S. J. Clarke, and A. L. Jackman
Leucovorin Rescue from Raltitrexed (Tomudex)-induced Antiproliferative Effects: In Vitro Cell Line and in Vivo Mouse Studies
Clin. Cancer Res., September 1, 2000; 6(9): 3646 - 3656.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
F. B. Turner, J. L. Andreassi II, J. Ferguson, S. Titus, A. Tse, S. M. Taylor, and R. G. Moran
Tissue-specific Expression of Functional Isoforms of Mouse Folylpoly-{{gamma}}-glutamate Synthetase: A Basis for Targeting Folate Antimetabolites
Cancer Res., December 1, 1999; 59(24): 6074 - 6079.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
F. M. Sirotnak
Enhancing Cytotoxic Sensitivity of Tumor Cells to Antifolates: Another Opportunity for Gene Therapy?
J Natl Cancer Inst, July 21, 1999; 91(14): 1178 - 1179.
[Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. C. Waltham, W.-W. Li, H. Gritsman, W. P. Tong, and J. R. Bertino
gamma -Glutamyl Hydrolase from Human Sarcoma HT-1080 Cells: Characterization and Inhibition by Glutamine Antagonists
Mol. Pharmacol., May 1, 1997; 51(5): 825 - 832.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
K. Roy, M. G. Egan, S. Sirlin, and F. M. Sirotnak
Posttranscriptionally Mediated Decreases in Folylpolyglutamate Synthetase Gene Expression in Some Folate Analogue-resistant Variants of the L1210 Cell. EVIDENCE FOR AN ALTERED COGNATE mRNA IN THE VARIANTS AFFECTING THE RATE OF DE NOVO SYNTHESIS OF THE ENZYME
J. Biol. Chem., March 14, 1997; 272(11): 6903 - 6908.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Yao, Z. Nimec, T. J. Ryan, and J. Galivan
Identification, Cloning, and Sequencing of a cDNA Coding for Rat [IMAGE]-Glutamyl Hydrolase
J. Biol. Chem., April 12, 1996; 271(15): 8525 - 8528.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Roy, K. Mitsugi, S. Sirlin, B. Shane, and F. M. Sirotnak
Different Antifolate-resistant L1210 Cell Variants with either Increased or Decreased Folylpolyglutamate Synthetase Gene Expression at the Level of mRNA Transcription
J. Biol. Chem., November 10, 1995; 270(45): 26918 - 26922.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. G. Egan, S. Sirlin, B. G. Rumberger, T. A. Garrow, B. Shane, and F. M. Sirotnak
Rapid Decline in Folylpolyglutamate Synthetase Activity and Gene Expression during Maturation of HL-60 Cells
J. Biol. Chem., March 10, 1995; 270(10): 5462 - 5468.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1986 by the American Association for Cancer Research.